Frederic Bigot

Angers, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 03, 2026

Sex disparities in lung cancer: Results of the KBP-2020-CPHG study.

Sex disparities in lung cancer: Results of the KBP-2020-CPHG study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 23, 2026

Blood Sample Preparation for Human Chemical Exposomics: Insights from Large-Scale Applications.

Blood Sample Preparation for Human Chemical Exposomics: Insights from Large-Scale Applications.

Journal: Environmental science & technology

Published: September 30, 2025

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

Journal: ESMO open

Published: June 06, 2025

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 25, 2025

Preventive Behaviors of French Cancer Patients and How They Changed During the COVID-19 Outbreak (PAPESCO-19 Study).

Preventive Behaviors of French Cancer Patients and How They Changed During the COVID-19 Outbreak (PAPESCO-19 Study).

Journal: International journal of public health

Published: February 24, 2025

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

Journal: ESMO open

Published: February 10, 2025

Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.

Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 20, 2024

Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.

Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.

Journal: Oncology and therapy

Published: November 15, 2024

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial.

Journal: Nature cancer

Published: November 13, 2024

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.

Journal: PloS one

Published: January 15, 2024

Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.

Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 02, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026